• Novavax flu vaccine matches and beats Sanofi rival in phase 3

    6 days ago - By Fierce Biotech

    Novavax's influenza vaccine NanoFlu has outperformed Sanofi's Fluzone Quadrivalent on measures of immunogenicity in a phase 3 trial. The trial hit its primary and key secondary endpoints, sending Novavax's stock up 40% and sparking talk of an accelerated FDA approval.
    Read more ...